10-Q: Sensus Healthcare Reports Q3 Loss Amid Revenue Decline

Sensus Healthcare reported a significant net loss in Q3 2025, driven by a 22% revenue decrease and substantial increases in operating expenses, despite an improved cash position.

Summary

• Sensus Healthcare, Inc. reported a net loss of $0.943 million for the three months ended September 30, 2025, a significant decline from a net income of $1.215 million in the prior-year period.
• Revenues decreased by 21.6% to $6.884 million for Q3 2025, down from $8.839 million in Q3 2024, primarily due to a lower number of units sold (16 vs. 27) and reduced sales to a large U.S. customer.
• Gross profit fell by 48.1% to $2.713 million in Q3 2025, with the gross profit percentage dropping to 39.1% from 59.1% in Q3 2024, impacted by lower sales and higher servicing costs.
• Total operating expenses surged by 41.0% to $5.282 million in Q3 2025, with Research and Development expenses doubling to $1.819 million due to lobbying costs, increased headcount, and next-generation product development.
• For the nine months ended September 30, 2025, the company recorded a net loss of $4.552 million, compared to a net income of $5.101 million in the same period last year.
• Year-to-date revenues decreased by 21.6% to $22.543 million, down from $28.741 million, with unit sales declining from 76 to 56.
• Cash and cash equivalents increased by $2.4 million to $24.453 million as of September 30, 2025, from $22.056 million at December 31, 2024, largely due to positive operating cash flow.
• Accounts receivable decreased by $10.4 million to $9.3 million, attributed to lower sales and extended payment terms with a primary customer.
• Inventories increased by $2.9 million to $13.0 million, in anticipation of increasing future sales.
• The company received a waiver from Comerica Bank for a default on its minimum profitability covenant as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company experienced a substantial decline in revenue and a swing to net losses for both the quarter and year-to-date periods, driven by lower unit sales and increased operating expenses. Gross profit margins also significantly eroded. While cash from operations improved and cash reserves increased, this was against a backdrop of severe underperformance in profitability and a debt covenant default. The high customer concentration and ongoing legal investigation add to the negative sentiment. Increased R&D for next-gen systems and lobbying for reimbursement are positive long-term investments but contribute to current losses.

Positives

• Net cash provided by operating activities significantly improved to $2.735 million for the nine months ended September 30, 2025, compared to a net cash used of $4 thousand in the prior year.
• Cash and cash equivalents increased by $2.4 million to $24.453 million as of September 30, 2025.
• Management believes current liquidity and borrowing capacity are sufficient to meet operating capital and funding requirements for the next 12 months.
• The "One Big Beautiful Bill Act" enacted in July 2025 is expected to decrease the timing of cash tax payments in future periods.
• The company received $0.3 million in Employee Retention Credits in Q2 2025.
• Research and development investment increased by 100% in Q3 and 118.5% YTD, focusing on next-generation systems and billing code reimbursement, which could drive future growth.

Negatives

• Net loss of $0.943 million for Q3 2025, a significant reversal from net income of $1.215 million in Q3 2024.
• Net loss of $4.552 million for the nine months ended September 30, 2025, compared to net income of $5.101 million in the prior-year period.
• Total revenues decreased by 21.6% for both the three and nine months ended September 30, 2025, primarily due to lower unit sales (16 units in Q3 2025 vs 27 in Q3 2024; 56 units YTD 2025 vs 76 YTD 2024).
• Gross profit decreased by 48.1% in Q3 2025 and 42.2% YTD 2025, with gross profit percentage falling to 39.1% (Q3) and 44.4% (YTD) from 59.1% and 60.3% respectively.
• Cost of sales increased by 16.7% in Q3 2025 and 10.5% YTD 2025, despite lower revenues, due to higher servicing costs and costs associated with the new placement program.
• Operating expenses increased significantly across all categories: G&A up 18.8% (Q3) and 29.8% (YTD), S&M up 15.4% (Q3) and 41.7% (YTD), and R&D up 100% (Q3) and 118.5% (YTD).
• Operating income swung to a loss of $2.569 million in Q3 2025 and $7.159 million YTD 2025, from positive income in the prior year.
• Accounts receivable decreased by $10.4 million, partly due to reduced sales and extended payment terms with a primary customer, indicating potential collection challenges or less favorable terms.
• The company defaulted on a minimum profitability covenant with Comerica Bank as of June 30, 2025, requiring a waiver.
• High customer concentration, with one U.S. customer accounting for 59% of Q3 revenue, 62% of YTD revenue, and 86% of accounts receivable.

Risks

• The possibility that inflationary pressures continue to impact sales, commodity and shipping prices, energy, and labor costs.
• The level and availability of government and/or third-party payor reimbursement for clinical procedures using products, and the willingness of healthcare providers to purchase products if reimbursement declines.
• The development by others of new products, treatments, or technologies that render current technology partially or wholly obsolete.
• Regulatory requirements applicable to the company and its competitors.
• The ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries, including tariffs and fluctuations in tariffs on exported equipment or imported materials.
• The performance of the company's information technology systems and its ability to maintain data security.
• The ability to obtain and maintain the intellectual property needed to adequately protect products, and the ability to avoid infringing or otherwise violating the intellectual property rights of third parties.
• Concentration of customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S. (59% of Q3 revenue, 62% of YTD revenue, and 86% of accounts receivable).
• Financial market instability or disruptions to the banking system due to bank failures impacting liquidity and capital requirements.
• Ongoing Department of Justice investigation regarding a physician's billing to Medicare using the company's SRT-100, with potential expansion to the company's involvement, and an inability to estimate associated costs.

Future Outlook

Management anticipates that the effective tax rate for the full year 2025 will continue to differ materially from the U.S. federal statutory rate of 21.0%, driven largely by the favorable impact of tax credits relative to pre-tax income. The "One Big Beautiful Bill Act" enacted in July 2025 is expected to decrease the timing of cash tax payments in future periods. The company continues to monitor geopolitical uncertainties and will address them in future disclosures if applicable. Management is taking actions, such as ordering inventory in advance, to minimize the effects of inflation on product cost and sales.

Management Comments

• "The decrease in revenue was primarily driven by a lower number of units sold... reflecting reduced sales to a large customer, slightly offset by revenue recognized from the new placement program under the Fair Deal Agreement."
• "The increase in cost of sales was primarily related to higher costs of servicing systems and the cost associated with the new placement program under the Fair Deal Agreement, which generates costs related to installation and training in advance of related revenues."
• "The decrease in gross profit was primarily driven by lower sales, higher costs of servicing systems, and the cost associated with the new placement program."
• "The net increase in general and administrative expense was primarily due to higher professional fees (IT and consult) and compensation."
• "The increase [in selling and marketing expense] was primarily driven by an increase in payroll cost due to commissions related to the new placement program and an increase in headcount."
• "The increase [in research and development expense] was primarily due to significant lobbying costs related to billing code reimbursement, increased headcount, and an increase in product development costs related to next generation systems."
• "The increase in the effective tax rate for the three months ended September 30, 2025 compared to the prior period was primarily attributable to an increase in the estimated tax credits that are expected to be generated and utilized in proportion to the amount of pretax profit."
• "Looking ahead, we anticipate that our effective tax rate for the full year 2025 will continue to differ materially from the U.S. federal statutory rate of 21.0%, driven largely by the favorable impact of these tax credits relative to our pre-tax income."
• "The decrease [in accounts receivable] was primarily due to the decrease in sales and concentration of sales to the Company's primary customer that is subject to extended payment terms."
• "The increase [in inventories] was primarily due to the anticipation of increasing future sales."
• "The Company believes that proceeds from maturing cash equivalents, as well as the Company's borrowing capacity under its existing line of credit and access to capital resources are sufficient to meet operating capital and funding requirements for the next 12 months from the date this quarterly report was issued."
• "We continue to monitor the impact of inflation and we are taking actions, such as ordering inventory in advance, to minimize its effects on our product cost and sales."

Industry Context

The company operates in the highly regulated U.S. dermatology market, where state regulatory approval is sometimes required for product use. Increased R&D spending on lobbying for billing code reimbursement suggests ongoing challenges or opportunities related to healthcare policy and payment structures for its SRT technology. The focus on "next generation systems" indicates a competitive environment requiring continuous innovation in radiation therapy devices for skin conditions. The formation of Sensus Healthcare Services, LLC to provide operational healthcare services, including leased equipment and personnel, reflects a trend towards broader service offerings in the medical device industry to capture recurring revenue and support customer adoption.

Legal Proceedings

• Department of Justice investigation commenced in 2015 regarding a physician's billing to Medicare using the company's SRT-100.
• The Department is considering expanding the investigation to determine the company's involvement in the physician's use of certain reimbursement codes.
• The company received two Civil Investigative Demands for documents and responses.
• The company disputes wrongdoing and states it does not submit claims for reimbursement or provide coding/billing advice.
• The Department has not made a determination on wrongdoing or legal action against the company.
• The company believes it has strong defenses and will vigorously defend itself if legal action is pursued.
• As of September 30, 2025, the company is unable to estimate the cost, if any, associated with this matter.

Stakeholder Impact

• Shareholders: Negative impact due to significant net losses, decreased revenues, and erosion of gross profit and stockholders' equity. The debt covenant default and ongoing legal investigation add uncertainty.
• Employees: Increased headcount in selling and marketing and R&D suggests continued investment in personnel, but overall financial performance could impact future compensation or job security.
• Customers: Reduced sales to a large U.S. customer indicates potential issues with key relationships or market demand. The new placement program aims to expand the customer base.
• Creditors (Comerica Bank): The company defaulted on a profitability covenant, requiring a waiver, which indicates increased risk for the lender, though no borrowings were outstanding.
• Suppliers: Inflationary pressures and advance inventory ordering could impact supplier relationships and terms.

Next Steps

• Continue monitoring the impact of inflation and implement actions to minimize its effects on product cost and sales.
• Address the Department of Justice investigation, vigorously defending against any allegations of wrongdoing.
• Focus on increasing future sales to utilize increased inventory levels.
• Manage the new placement program under the Fair Deal Agreement to ensure related revenues catch up with initial installation and training costs.
• Continue product development for next-generation systems and lobbying efforts for billing code reimbursement.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, with a substantial decline in revenue and a swing from net income to considerable net losses for both the quarter and year-to-date periods. Gross profit margins have been severely impacted, and operating expenses have surged. The default on a debt covenant, even with a waiver, signals underlying financial weakness. While cash from operations improved, this is overshadowed by the overall lack of profitability. The high customer concentration and an unresolved Department of Justice investigation present significant unquantified risks. These factors collectively point to a challenging outlook and warrant a "sell" recommendation for investors.

Keywords

Sensus Healthcare, SRTS, Medical Devices, Radiation Therapy, SRT Technology, Dermatology, Oncology, Quarterly Report, Financial Results, Revenue Decline, Net Loss, Operating Expenses, Customer Concentration, Debt Covenant, Legal Proceedings, Healthcare Technology, Medical Equipment